Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TFC-003 in Primary Open-Angle Glaucoma or Ocular Hypertension
NCT07662759Phase 3Recruiting
- Sponsor
- Kukje Pharm
- Start
- Dec 2025
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of TFC-003 in primary open-angle glaucoma (POAG) and ocular hypertension (3 arms), sponsored by Kukje Pharm. Primary endpoint: Mean change in diurnal intraocular pressure at 12 weeks. Started Dec 2025; status: recruiting.
02
Drugs
TFC-003
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT07662759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07662759.